Truist raises Zimmer Biomet stock price target on robotics progress
Truist Securities raised Zimmer Biomet's (ZBH) price target to $114 from $106, citing 3.7% Q3 organic revenue growth, though EPS missed estimates. The stock is up 13% in a week. Analysts note progress in robotics and hip segments, but caution on knee division weakness and future risks. Other analysts also raised targets, with Stifel at $125 and Jefferies at $120.
How this was made
The 30-second read
Why it matters
Earnings beat and higher targets are likely to drive short‑term buying interest.
Market read
ZBH's earnings beat and analyst upgrades create a bullish catalyst for the stock and may influence the medical device sector.
What to watch
Potential supply‑chain or regulatory risks in the knee product line could dampen momentum.
Background
The article summarizes analyst price‑target revisions and ZBH's Q3 earnings, highlighting revenue growth and product segment performance.
Ticker impact
Truist raised its price target on Zimmer Biomet to $114 and reported Q3 earnings that beat expectations, with revenue of $2.06B and EPS of $1.90.
likely upward pressure as investors price in higher target and earnings beat
Multiple analysts raised targets and the company posted better-than-expected results, indicating improved fundamentals.
Market effects
Positive earnings and target upgrades may lift the broader medical device sector.
U.S. healthcare stocks could see modest gains.
Limited to U.S. equities; no direct global impact.
Counterpoint
If the knee segment weakness persists, the upside may be limited despite the upgrades.
Key entities
- companyZimmer Biomet Holdings Inc.
Medical device maker reporting Q3 results.
- analystTruist Securities
Raised price target to $114.


